Clearmind Medicine shares are trading higher after the company announcedthat the Johns Hopkins Medicine Institutional Review Board has granted approval for its ongoing Phase I/II clinical trial of CMND-100.

Benzinga Newsdesk www.benzinga.com Positive 95.1%

Neg 0% Neu 0% Pos 95.1%

Comments

No comments yet. Be the first!